

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lindfors et al.
Serial No. : 09/581,959
Filed : June 19, 2000
For : NEW IMPROVED FORMULATION
Examiner : To be assigned
Group Art Unit : To be assigned



RECEIVED
JAN 04 2002
TECH-CENTER 1600/2900

I hereby certify that this paper is being deposited
with the United States Postal Service as
first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Paul Diamond	48,532
Attorney Name	PTO Reg. No.
<i>Paul Diamond</i>	<i>11 October 2001</i>
Signature	Date of Signature

Assistant Commissioner for Patents
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)(3)**

Sir:

The above-referenced application is a U.S. national phase application, filed pursuant to 35 U.S.C §371, of International Patent Appln. No. PCT/SE00/00664 (the "PCT application"). Applicants submit this communication and the attached Form PTO-1449 in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. A copy of each of the documents listed in the Form PTO-1449 is enclosed as part of this communication unless otherwise specified herein.

The references listed in the accompanying Form PTO-1449 are related applications or documents cited in either the specification of the above-referenced application or the International Search Report ("ISR") that issued in connection with the PCT application. A copy of the published PCT application, WO 00/61111, the ISR attached to the PCT application and the International Preliminary Examination Report that issued in the PCT application is enclosed.

Specifically, one of the references listed in the attached form PTO-1449 is co-pending, commonly-assigned U.S. Application Serial No. 09/171,950, filed October 29, 1998. A copy of U.S. Application Serial No. 09/171,950, as filed, is enclosed.

The following two references which are cited in the "Background Art" section of the specification and listed in the attached Form PTO-1449 are entire books:

1. Aulton ME, Pharmaceutics - The science of dosage form design, Churchill Livingstone 1988, Hong Kong; and
2. de Boer ABG (Ed.), Drug Absorption Enhancement, Harwood Academic Publishers, 1994.

Applicants have not enclosed copies of the cited book references. These references merely describe the state of the art and are not material to the patentability of the present invention. Therefore, Applicants submit that they have fulfilled their duty of disclosure under U.S. patent law and are not required to submit copies of the book references.

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits according to 37 C.F.R. §1.97(b)(3). Therefore, no fee is due in connection with this filing. However, should any fee be deemed necessary in connection with this filing, the Assistant Commissioner is hereby authorized to charge Deposit Account No. 23-1703.

Dated: October 11, 2001

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Paul Diamond", written over a horizontal line.

Paul Diamond
Reg. No. 48,532
Agent for Applicants

Customer No. 007470
(212) 819-8200